The Valley Desk

NCT03679598 · Interventional trial

Alvelestat (MPH966) for the Treatment of ALpha-1 ANTitrypsin Deficiency

Overall registry status Completed

Phase 2

Conditions Alpha-1 Antitrypsin Deficiency (AATD), Emphysema or COPD, Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I Mutations

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov